These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
168 related articles for article (PubMed ID: 11721634)
61. Proteome of metastatic canine mammary carcinomas: similarities to and differences from human breast cancer. Klopfleisch R; Klose P; Weise C; Bondzio A; Multhaup G; Einspanier R; Gruber AD J Proteome Res; 2010 Dec; 9(12):6380-91. PubMed ID: 20932060 [TBL] [Abstract][Full Text] [Related]
62. Identification of Up- and Down-Regulated Proteins in Pemetrexed-Resistant Human Lung Adenocarcinoma: Flavin Reductase and Calreticulin Play Key Roles in the Development of Pemetrexed-Associated Resistance. Chou HC; Chen JY; Lin DY; Wen YF; Lin CC; Lin SH; Lin CH; Chung TW; Liao EC; Chen YJ; Wei YS; Tsai YT; Chan HL J Proteome Res; 2015 Nov; 14(11):4907-20. PubMed ID: 26452990 [TBL] [Abstract][Full Text] [Related]
63. An introduction into proteomics and its clinical applications. Ahram M Saudi Med J; 2007 Apr; 28(4):499-507. PubMed ID: 17457467 [TBL] [Abstract][Full Text] [Related]
64. Proteome analysis of hepatocellular carcinoma by two-dimensional difference gel electrophoresis: novel protein markers in hepatocellular carcinoma tissues. Sun W; Xing B; Sun Y; Du X; Lu M; Hao C; Lu Z; Mi W; Wu S; Wei H; Gao X; Zhu Y; Jiang Y; Qian X; He F Mol Cell Proteomics; 2007 Oct; 6(10):1798-808. PubMed ID: 17627933 [TBL] [Abstract][Full Text] [Related]
65. Proteomic profiling of infiltrating ductal carcinoma reveals increased cellular interactions with tissue microenvironment. Gormley M; Tchafa A; Meng R; Zhong Z; Quong AA J Proteome Res; 2012 Apr; 11(4):2236-46. PubMed ID: 22356716 [TBL] [Abstract][Full Text] [Related]
66. Large scale protein profiling by combination of protein fractionation and multidimensional protein identification technology (MudPIT). Chen EI; Hewel J; Felding-Habermann B; Yates JR Mol Cell Proteomics; 2006 Jan; 5(1):53-6. PubMed ID: 16272560 [TBL] [Abstract][Full Text] [Related]
67. A proteomics approach to find a new breast cancer-specific antigenic marker. Kobayashi R Clin Cancer Res; 2001 Nov; 7(11):3325-7. PubMed ID: 11705843 [No Abstract] [Full Text] [Related]
69. Proteome profiling of breast tumors by gel electrophoresis and nanoscale electrospray ionization mass spectrometry. Alldridge L; Metodieva G; Greenwood C; Al-Janabi K; Thwaites L; Sauven P; Metodiev M J Proteome Res; 2008 Apr; 7(4):1458-69. PubMed ID: 18257521 [TBL] [Abstract][Full Text] [Related]
70. Proteomic identification of 14-3-3 sigma as a common component of the androgen receptor and the epidermal growth factor receptor signaling pathways of the human prostate epithelial cell line M12. Huang D; Liu X; Plymate SR; Idowu M; Grimes M; Best AM; McKinney JL; Ware JL Oncogene; 2004 Sep; 23(41):6881-9. PubMed ID: 15300238 [TBL] [Abstract][Full Text] [Related]
71. Biomarkers of chemotherapy resistance in breast cancer identified by proteomics: current status. Hodgkinson VC; Eagle GL; Drew PJ; Lind MJ; Cawkwell L Cancer Lett; 2010 Aug; 294(1):13-24. PubMed ID: 20176436 [TBL] [Abstract][Full Text] [Related]
72. Irradiated breast cancer patients demonstrate subgroup-specific regularities in protein expression patterns of circulating leukocytes. Yeghiazaryan K; Mamlouk S; Trog D; Moenkemann H; Braun M; Kuhn W; Schild H; Golubnitschaja O Cancer Genomics Proteomics; 2007; 4(6):411-8. PubMed ID: 18204204 [TBL] [Abstract][Full Text] [Related]
73. Efp targets 14-3-3 sigma for proteolysis and promotes breast tumour growth. Urano T; Saito T; Tsukui T; Fujita M; Hosoi T; Muramatsu M; Ouchi Y; Inoue S Nature; 2002 Jun; 417(6891):871-5. PubMed ID: 12075357 [TBL] [Abstract][Full Text] [Related]
74. Comparison of tear protein levels in breast cancer patients and healthy controls using a de novo proteomic approach. Böhm D; Keller K; Pieter J; Boehm N; Wolters D; Siggelkow W; Lebrecht A; Schmidt M; Kölbl H; Pfeiffer N; Grus FH Oncol Rep; 2012 Aug; 28(2):429-38. PubMed ID: 22664934 [TBL] [Abstract][Full Text] [Related]
75. Expanding the protein catalogue in the proteome reference map of human breast cancer cells. Pucci-Minafra I; Cancemi P; Fontana S; Minafra L; Feo S; Becchi M; Freyria AM; Minafra S Proteomics; 2006 Apr; 6(8):2609-25. PubMed ID: 16526084 [TBL] [Abstract][Full Text] [Related]
76. Proteomics: techniques and applications in cancer research. Schramm A; Apostolov O; Sitek B; Pfeiffer K; Stühler K; Meyer HE; Havers W; Eggert A Klin Padiatr; 2003; 215(6):293-7. PubMed ID: 14677091 [TBL] [Abstract][Full Text] [Related]
77. Epigenetic and proteolytic inactivation of 14-3-3sigma in breast and prostate cancers. Horie-Inoue K; Inoue S Semin Cancer Biol; 2006 Jun; 16(3):235-9. PubMed ID: 16682214 [TBL] [Abstract][Full Text] [Related]
78. Breast cancer: when proteomics challenges biological complexity. Hondermarck H Mol Cell Proteomics; 2003 May; 2(5):281-91. PubMed ID: 12775769 [TBL] [Abstract][Full Text] [Related]
79. Development of an antibody proteomics system using a phage antibody library for efficient screening of biomarker proteins. Imai S; Nagano K; Yoshida Y; Okamura T; Yamashita T; Abe Y; Yoshikawa T; Yoshioka Y; Kamada H; Mukai Y; Nakagawa S; Tsutsumi Y; Tsunoda S Biomaterials; 2011 Jan; 32(1):162-9. PubMed ID: 20933274 [TBL] [Abstract][Full Text] [Related]